Long-term outcomes in high-risk patients with non-ST-segment elevation myocardial infarction

Area of Science:

• Cardiology
• Clinical Medicine

Background:

• Evidence-based therapies have improved acute coronary syndrome (ACS) survival, leading to more patients living beyond 12 months.
• Non-ST-segment elevation myocardial infarction (NSTEMI) patients have not seen outcome improvements matching ST-segment elevation myocardial infarction (STEMI) patients.
• NSTEMI patients often present with complex phenotypes, including older age, comorbidities, and prior myocardial infarction (MI), complicating treatment decisions.

Purpose of the Study:

• To review the need for enhanced long-term management strategies for NSTEMI patients surviving ≥12 months post-MI.
• To highlight the importance of ongoing risk assessment for bleeding and ischemia in all post-MI patients.
• To address the challenges in determining optimal treatment durations, particularly dual antiplatelet therapy (DAPT), for high-risk NSTEMI survivors.

Main Methods:

• Review of existing literature and clinical trial data, including subgroup analyses from DAPT and PEGASUS-TIMI 54 trials.
• Examination of risk-benefit assessments for long-term therapies in complex NSTEMI patient populations.
• Focus on objective measures for ongoing risk stratification (bleeding and ischemia).

Main Results:

• Long-term dual antiplatelet therapy (DAPT) has shown benefits in cardiovascular outcomes for some post-MI patients but increases bleeding risk.
• Data suggest that the standard 12-month DAPT duration may not be optimal for all high-risk NSTEMI patients.
• Studies indicate that NSTEMI patients, particularly those with prior MI and other risk factors, may benefit from extended DAPT, albeit with increased bleeding.

Conclusions:

• More research is urgently needed to define optimal long-term management, including DAPT duration, for high-risk NSTEMI patients surviving ≥12 months post-MI.
• Continuous risk assessment using objective measures is crucial for guiding treatment decisions in stable post-MI patients.
• Balancing the cardiovascular benefits against bleeding risks associated with extended DAPT in stable NSTEMI patients requires further investigation.